Crescent Biopharma Statistics
Total Valuation
CBIO has a market cap or net worth of $638.04 million. The enterprise value is $426.49 million.
Important Dates
The next estimated earnings date is Saturday, May 23, 2026, after market close.
| Earnings Date | May 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CBIO has 33.21 million shares outstanding.
| Current Share Class | 27.56M |
| Shares Outstanding | 33.21M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +18.68% |
| Owned by Insiders (%) | 5.16% |
| Owned by Institutions (%) | 44.61% |
| Float | 14.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 58.84 |
| Forward PS | 437.87 |
| PB Ratio | 3.21 |
| P/TBV Ratio | 3.21 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 39.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.56, with a Debt / Equity ratio of 0.01.
| Current Ratio | 6.56 |
| Quick Ratio | 6.41 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -69.85 |
Financial Efficiency
Return on equity (ROE) is -160.75% and return on invested capital (ROIC) is -82.72%.
| Return on Equity (ROE) | -160.75% |
| Return on Assets (ROA) | -69.15% |
| Return on Invested Capital (ROIC) | -82.72% |
| Return on Capital Employed (ROCE) | -74.74% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $246,455 |
| Profits Per Employee | -$3.50M |
| Employee Count | 44 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CBIO has paid $2.00 million in taxes.
| Income Tax | 2.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 11.93 |
| 200-Day Moving Average | 12.77 |
| Relative Strength Index (RSI) | 79.57 |
| Average Volume (20 Days) | 249,314 |
Short Selling Information
The latest short interest is 1.45 million, so 4.36% of the outstanding shares have been sold short.
| Short Interest | 1.45M |
| Short Previous Month | 1.45M |
| Short % of Shares Out | 4.36% |
| Short % of Float | 10.04% |
| Short Ratio (days to cover) | 8.51 |
Income Statement
In the last 12 months, CBIO had revenue of $10.84 million and -$153.94 million in losses. Loss per share was -$12.81.
| Revenue | 10.84M |
| Gross Profit | 10.84M |
| Operating Income | -152.63M |
| Pretax Income | -151.94M |
| Net Income | -153.94M |
| EBITDA | -152.55M |
| EBIT | -152.63M |
| Loss Per Share | -$12.81 |
Full Income StatementBalance Sheet
The company has $213.19 million in cash and $1.64 million in debt, with a net cash position of $211.55 million or $6.37 per share.
| Cash & Cash Equivalents | 213.19M |
| Total Debt | 1.64M |
| Net Cash | 211.55M |
| Net Cash Per Share | $6.37 |
| Equity (Book Value) | 203.01M |
| Book Value Per Share | 5.99 |
| Working Capital | 200.58M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$71.53 million and capital expenditures -$919,000, giving a free cash flow of -$72.45 million.
| Operating Cash Flow | -71.53M |
| Capital Expenditures | -919,000 |
| Depreciation & Amortization | 84,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -72.45M |
| FCF Per Share | -$2.18 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -1,407.52% |
| Pretax Margin | -1,401.16% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -24.13% |
| FCF Yield | -11.36% |
Analyst Forecast
The average price target for CBIO is $26.67, which is 38.83% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $26.67 |
| Price Target Difference | 38.83% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 57.47% |
| EPS Growth Forecast (5Y) | -20.67% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CBIO has an Altman Z-Score of 2.1 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.1 |
| Piotroski F-Score | 1 |
